Interesting article on Herceptin. Notice the one statement below. You could replace the word Herceptin with many other cancer drugs. �But, like other great advances in cancer treatment, the path to success was not easy. Herceptin�s rise to prominence actually took many years and required much hard work by numerous doctors and thousands of patients.� http://www.curetoday.com/currentissue/features/herceptin/index.html Sooner
How is GNBT doing?--it was only a matter of time before the Asian flu hype torpedoed that stock. I see GNBT issued one of its fluff PRs this morning but it didn't help the stock. Why didn't you sell GNBT at $5, Larry?--any idiot knew the bubble would burst! And your SGEN is going down the tubes also.
It seems to me that breast cancer may be typical of others cancers we're fighting. I.E. only part of the cancer has what we're targeting, and even if we're totally successful in targeting that part, we cannot completely eliminate the cancer without the assistance of other agents that targets what remains.
Herceptin is successful in patients that are among the 25% that have Her2 because it is used with other forms of chemo. Virtually all TAP drugs in trial to date have only been given as monotherapies. When these drugs have produced stable disease or better in many patients they may have totally eliminated the specific form of cancer they targeted, but the total cancer adapted to growing again without that form.
My point is, if the TAP drug had been used with other drugs that attack the remainder of the cancer, together they might have eliminated it completely, or at least had a stronger effect on it, sustaining life much longer. Eventually it may turn out that multiple TAP drugs are the answer.
It seems to me that cancer is an evolving disease, just as viruses seem to be. As you attack cancer long enough with the same product, it builds a defense against that product. Perhaps the right answer not only involves multiple drugs, but also alternating the drugs in such a way as to prevent the cancer from building such a defense.
It was probably ten or more years ago that I was told something that was found to have occurred in the Oncolysin Trials. It seems that refractory patients that developed a resistance to Oncolysin could again successfully be treated by the drugs the had previously become refractory to. Had the trial protocol permitted it, they might have tried the Oncolysin again if they became refractory to the drugs again. Unfortunately, trials do not permit such experimentation.